These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27387327)

  • 1. Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
    Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thezenas S; Jacot W
    BMC Cancer; 2016 Jul; 16():428. PubMed ID: 27387327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?
    Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thézenas S; Jacot W
    Int J Cancer; 2016 Nov; 139(10):2299-311. PubMed ID: 27464303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
    Darlix A; Hirtz C; Thezenas S; Maceski A; Gabelle A; Lopez-Crapez E; De Forges H; Firmin N; Guiu S; Jacot W; Lehmann S
    BMC Cancer; 2019 Jan; 19(1):110. PubMed ID: 30700265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
    Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
    PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer.
    Lee SB; Lee JW; Yu JH; Ko BS; Kim HJ; Son BH; Gong G; Lee HJ; Kim SB; Jung KH; Ahn JH; Lee W; Sung J; Ahn SH
    BMC Cancer; 2014 Dec; 14():929. PubMed ID: 25491647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
    Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
    Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
    Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
    Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
    Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
    J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
    Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
    Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.